Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Moodys
McKinsey
Baxter
Boehringer Ingelheim

Last Updated: November 30, 2021

DrugPatentWatch Database Preview

EISAI INC Company Profile


Email this page to a colleague

« Back to Dashboard

Summary for EISAI INC
International Patents:493
US Patents:15
Tradenames:9
Ingredients:8
NDAs:13
Drug Master File Entries: 1

Drugs and US Patents for EISAI INC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes 7,253,286 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Eisai Inc DAYVIGO lemborexant TABLET;ORAL 212028-002 Apr 7, 2020 RX Yes Yes 10,188,652 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 RX Yes Yes 6,214,865 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-002 Feb 13, 2015 RX Yes Yes 10,407,393 ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Eisai Inc LENVIMA lenvatinib mesylate CAPSULE;ORAL 206947-001 Feb 13, 2015 RX Yes No 7,253,286 ⤷  Free Forever Trial Y Y ⤷  Free Forever Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 DISCN Yes No 6,740,669*PED ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Eisai Inc ARICEPT donepezil hydrochloride SOLUTION;ORAL 021719-001 Oct 18, 2004 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EISAI INC

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-001 Nov 14, 2008 8,076,362*PED ⤷  Free Forever Trial
Eisai Inc ARICEPT donepezil hydrochloride TABLET;ORAL 020690-001 Nov 25, 1996 6,372,760 ⤷  Free Forever Trial
Eisai Inc ARICEPT donepezil hydrochloride TABLET;ORAL 022568-001 Jul 23, 2010 4,895,841 ⤷  Free Forever Trial
Eisai Inc LUSEDRA fospropofol disodium SOLUTION;INTRAVENOUS 022244-001 Dec 12, 2008 6,872,838 ⤷  Free Forever Trial
Eisai Inc HALAVEN eribulin mesylate SOLUTION;INTRAVENOUS 201532-001 Nov 15, 2010 6,469,182 ⤷  Free Forever Trial
Eisai Inc BANZEL rufinamide TABLET;ORAL 021911-003 Nov 14, 2008 7,750,028*PED ⤷  Free Forever Trial
Eisai Inc BANZEL rufinamide SUSPENSION;ORAL 201367-001 Mar 3, 2011 7,750,028*PED ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for EISAI INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 23 mg ➤ Subscribe 2013-07-09
➤ Subscribe Oral Suspension 40 mg/mL ➤ Subscribe 2014-06-16
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2010-06-30
➤ Subscribe Capsules 4 mg and 10 mg ➤ Subscribe 2019-02-13
➤ Subscribe Tablets 100 mg, 200 mg and 400 mg ➤ Subscribe 2012-11-14
➤ Subscribe Tablets 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg ➤ Subscribe 2016-10-24

International Patents for EISAI INC Drugs

Country Patent Number Estimated Expiration
Cyprus 1116312 ⤷  Free Forever Trial
Japan 6659681 ⤷  Free Forever Trial
Serbia 52752 ⤷  Free Forever Trial
World Intellectual Property Organization (WIPO) 2016031841 ⤷  Free Forever Trial
Slovenia 1698623 ⤷  Free Forever Trial
China 1680402 ⤷  Free Forever Trial
European Patent Office 1596855 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for EISAI INC Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1300396 2012/049 Ireland ⤷  Free Forever Trial PRODUCT NAME: PERAMPANEL, OPTIONALLY A SALT OR HYDRATE THEREOF.; REGISTRATION NO/DATE: EU/1/12/776/001-EU/1/12/776/016 20120723
0994863 SPC/GB07/041 United Kingdom ⤷  Free Forever Trial PRODUCT NAME: CRYSTAL MODIFICATION A OF RUFINAMIDE; REGISTRATION NO/DATE: EU/1/06/378/001 - 015
1087960 132011901976051 Italy ⤷  Free Forever Trial PRODUCT NAME: ERIBULINA(HALAVEN); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/678/001-002, 20110317
1698623 PA2015039 Lithuania ⤷  Free Forever Trial PRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
1300396 1290045-2 Sweden ⤷  Free Forever Trial PRODUCT NAME: PERAMPANEL OCH SALTER OCH HYDRATER DAERAV; REG. NO/DATE: EU/1/12/776/001 20120723
1087960 11C0038 France ⤷  Free Forever Trial PRODUCT NAME: ERIBULINE, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER MESYLATE D'ERIBULINE; REGISTRATION NO/DATE: EU/1/11/678/001 20110317
0994863 91345 Luxembourg ⤷  Free Forever Trial CERTIFICATE NAME: RUFINAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES (INOVELON); FIRST REGISTRATION DATE: 20070116
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Moodys
Harvard Business School
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.